Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials

•SPLENDOUR and AMGEN-249 tested denosumab and chemotherapy in advanced NSCLC.•The pooled analysis aims to conclude about the impact of denosumab in NSCLC.•The analysis was based on 514 patients from SPLENDOUR and 226 from AMGEN-249.•No statistically significant improvement was found, neither for PFS nor for OS.•Denosumab did not add any meaningful benefit in any of the subgroups.